[SCHEDULE 13D/A] ANI Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

ANI Pharmaceuticals' Schedule 13D/A reports that Meridian Venture Partners II entities and affiliated persons beneficially own a combined 1,034,570 shares of ANI common stock, representing 4.8% of the class. The filing breaks ownership across Meridian Venture Partners II GP, L.P., Meridian Venture Partners II, L.P., Meridian Venture Partners II, Co., and Robert E. Brown, Jr., with shared voting and dispositive power over 1,014,381 shares held by the Meridian entities and sole voting/dispositive power over 20,189 shares held directly by Mr. Brown.

The statement provides the issuer's principal office address and is signed by Robert E. Brown, Jr. as of 08/21/2025. No additional transaction details, intentions regarding the investment, or legal proceedings are disclosed in the provided excerpt.

Positive

• Transparent disclosure of aggregate beneficial ownership of 1,034,570 shares, helping investors understand shareholder composition
• Clear allocation of voting and dispositive powers across Meridian entities and Robert E. Brown, Jr., including specific share counts

Negative

• No stated intent or plan regarding the investment is included, so the filing does not indicate any proposed corporate actions
• Ownership below 5% (4.8%), which is material for disclosure but does not represent a controlling or clearly activist stake

Insights

Financial Analyst

TL;DR: Meridian and affiliates report a 4.8% stake in ANIP, indicating a meaningful but non-controlling position with shared voting power.

The filing discloses aggregate beneficial ownership of 1,034,570 shares (4.8%), with the Meridian entities sharing voting and dispositive power over 1,014,381 shares and Robert E. Brown, Jr. holding 20,189 shares of sole power. For investors, this is a notable ownership disclosure below the 5% mark that often triggers heightened market attention; however, the document does not state any intent to pursue board representation, strategic changes, or transactions. Absent further detail, the impact on ANI's operations and capital structure appears limited.

Corporate Governance Expert

TL;DR: Reported ownership is material for disclosure but does not convey control or explicit activist intentions.

The schedule properly identifies the reporting persons and allocates voting and dispositive powers, showing shared control at the Meridian entity level and limited sole control by Mr. Brown over 20,189 shares. The filing contains signatures and the issuer address but omits any stated purpose or plans related to governance changes. From a governance perspective, this is routine ownership reporting rather than a clear sign of imminent corporate action.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 10)

ANI Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

00182C103

(CUSIP Number)

Robert A. Graham, MVP Capital
259 N. Radnor-Chester Road, Suite 130
Radnor, PA, 19087
(610) 254-2999

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

08/21/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 00182C103

1

Name of reporting person

Meridian Venture Partners II GP, L.P. ("GP")

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,014,381.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,014,381.00

11

Aggregate amount beneficially owned by each reporting person

1,014,381.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.7 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP No. 00182C103

1

Name of reporting person

Meridian Venture Partners II, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,014,381.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,014,381.00

11

Aggregate amount beneficially owned by each reporting person

1,014,381.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.7 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP No. 00182C103

1

Name of reporting person

Meridian Venture Partners II, Co.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,014,381.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,014,381.00

11

Aggregate amount beneficially owned by each reporting person

1,014,381.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.7 %

14

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13D

CUSIP No. 00182C103

1

Name of reporting person

Robert E. Brown, Jr.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 20,189.00
8	Shared Voting Power 1,014,381.00
9	Sole Dispositive Power 20,189.00
10	Shared Dispositive Power 1,014,381.00

11

Aggregate amount beneficially owned by each reporting person

1,034,570.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.8 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, $0.0001 par value per share
(b)	Name of Issuer: ANI Pharmaceuticals, Inc.
(c)	Address of Issuer's Principal Executive Offices: 210 Main Street West, Baudette, MINNESOTA , 56623.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Meridian Venture Partners II GP, L.P. ("GP")

Signature:	/s/ Robert E. Brown, Jr.
Name/Title:	Robert E. Brown, Jr.
Date:	08/21/2025

Meridian Venture Partners II, L.P.

Signature:	/s/ Robert E. Brown, Jr.
Name/Title:	Robert E. Brown, Jr.
Date:	08/21/2025

Meridian Venture Partners II, Co.

Signature:	/s/ Robert E. Brown, Jr.
Name/Title:	Robert E. Brown, Jr.
Date:	08/21/2025

Robert E. Brown, Jr.

Signature:	/s/ Robert E. Brown, Jr.
Name/Title:	Robert E. Brown, Jr.
Date:	08/21/2025

FAQ

How many ANI Pharmaceuticals (ANIP) shares do Meridian Venture Partners II and affiliates report owning?

The filing reports an aggregate of 1,034,570 shares, representing 4.8% of ANI's common stock.

What voting and dispositive power is disclosed in the Schedule 13D/A for ANIP?

Meridian entities report shared voting and dispositive power over 1,014,381 shares; Robert E. Brown, Jr. reports sole voting and dispositive power over 20,189 shares.

Does the filing state any plans to change ANI Pharmaceuticals' management or strategy?

No. The provided excerpt contains no statement of intent to pursue management changes, board representation, or other strategic actions.

When was the Schedule 13D/A signed for ANI Pharmaceuticals (ANIP)?

The signatures in the document are dated 08/21/2025 by Robert E. Brown, Jr.

Which entities are listed as reporting persons on the ANIP Schedule 13D/A?

Reported persons are Meridian Venture Partners II GP, L.P., Meridian Venture Partners II, L.P., Meridian Venture Partners II, Co., and Robert E. Brown, Jr.